Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Acute hepatitis C in 2005].

Eric Nguyen-Khac1

  • 1Service d'Hépato-Gastroentérologie, CHU d'Amiens, Place Victor Pauchet, 80054 Amiens Cedex 1. nguyen-khac.eric@chu-amiens.fr

Gastroenterologie Clinique Et Biologique
|March 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.

The lancet. Gastroenterology & hepatology·2026
Same author

Second-Line Practices in the Era of Immunotherapy in HCC: The CHIEF Cohort.

JHEP reports : innovation in hepatology·2026
Same author

Alcohol induces sorafenib resistance in hepatocellular carcinoma: A translational study.

Journal of molecular medicine (Berlin, Germany)·2026
Same author

Real-World Outcomes of Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

Real-life data on hepatocellular carcinoma in the French prospective CHIEF cohort in the era of immunotherapy.

European journal of gastroenterology & hepatology·2025
Same author

Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled trial.

Journal of hepatology·2025

Current acute hepatitis C treatment focuses on delayed intervention for spontaneous recovery. Pegylated interferon monotherapy for six months is highly effective, with combination therapy showing no added benefit.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Virology

Background:

  • Epidemiology of acute hepatitis C has shifted, with decreased post-transfusion cases and increased prevalence among intravenous drug users.
  • Recent trends show a younger patient demographic and a higher rate of spontaneous favorable outcomes compared to pre-1995 data.
  • Understanding spontaneous cure predictors is crucial to avoid unnecessary treatment.

Purpose of the Study:

  • To review recent literature on acute hepatitis C.
  • To identify the optimal current therapeutic strategy for acute hepatitis C.
  • To guide treatment decisions based on evolving epidemiological and clinical data.

Main Methods:

  • Literature review of recent studies on acute hepatitis C.
  • Analysis of epidemiological trends and transmission modes.

Related Experiment Videos

  • Evaluation of treatment outcomes and predictive factors for spontaneous cure.

    • Main Results:

    • A waiting period of 8-12 weeks post-symptoms is recommended to assess for spontaneous resolution.
    • Treatment decisions should be made within the first six months for better outcomes.
    • Pegylated interferon monotherapy for six months achieves over 90% sustained viral response.
    • Combination therapy with interferon and ribavirin offers no additional benefit.

    Conclusions:

    • Non-treatment is advised for acute hepatitis C cases with predicted spontaneous favorable outcomes.
    • Early treatment within six months, primarily with pegylated interferon monotherapy, is the recommended strategy.
    • The evolving epidemiology necessitates updated therapeutic guidelines for acute hepatitis C.